When it comes to your health, what actually works matters most
But pharmaceutical firms are already making adjustments overseas: Eli Lilly recently raised its UK GLP-1 prices by 170% to offset possible MFN-related revenue losses and maintain current pricing levels in the U.S
Lab Monitoring A maintenance plan should look beyond the scale
Instead, Insufficient head-to-head comparisons: Cross-trial comparisons with semaglutide, tirzepatide, cagrilintide, petrelintide, or retatrutide are confounded by different populations, durations, estimands, and trial designs
Telogen effluvium from rapid metabolic shifts The most common cause of GLP-1 related hair loss is telogen effluvium, a condition where a large percentage of hair follicles simultaneously shift from the anagen (growth) phase to the telogen (resting) phase